Nov 14 (Reuters) - India's Glenmark Pharmaceuticals GLEN.NS reported a 72% jump in second-quarter adjusted profit on Friday, on recovery in key North American and European markets.
The drugmaker reported a consolidated net profit of 6.1 billion rupees ($69.4 million) for the quarter ended September 30, up from 3.54 billion rupees a year ago.
Total revenue from operations rose 76% to 60.47 billion rupees during the quarter.
For further earnings highlights, click here.
KEY CONTEXT
Its secondary sales growth from India formulation business grew 10.8%, while net sales from Glenmark's core businesses in North America and Europe rose 7.4% and 8.5%, respectively.
The Indian pharmaceutical market grew 7.3% in value in September, driven by strong sales in cardiovascular, anti-diabetic, and anti-infectives therapies, according to data from PharmaRack.
Peers Torrent Pharma TORP.NS posted a profit rise on strong domestic demand for its cardiovascular and anti-diabetic drugs while Mankind Pharma MNKI.NS reported a fourth straight quarter of profit decline as tax cuts hurt supply chain.
PEER COMPARISON
Valuation (next 12 months)
Estimates (next 12 months)
Analysts' sentiment
RIC
PE
EV/EBITDA
Price/Sales
Revenue growth(%)
profit growth(%)
Mean rating *
# of analysts
Stock to price target**
Div yield (%)
Glenmark Pharmaceuticals Ltd
GLEN.NS
24.58
15.49
NULL
10.39
30.48
BUY
9
0.80
0.20
Mankind Pharma Ltd
MNKI.NS
38.54
25.43
5.97
14.25
18.67
BUY
16
0.85
0.04
Torrent Pharmaceuticals Ltd
TORP.NS
47.00
27.20
8.46
14.42
20.35
BUY
30
0.96
0.84
J B Chemicals and Pharmaceuticals Ltd
JBCH.NS
32.30
21.04
5.91
11.50
18.01
BUY
11
0.92
0.67
* The mean of analyst ratings standardised to a scale of Strong Buy, Buy, Hold, Sell, and Strong Sell
** The ratio of the stock's last close to analysts' mean price target; a ratio above 1 means the stock is trading above the PT
JULY TO SEPTEMBER STOCK PERFORMANCE
-- All data from LSEG
-- $1 = 87.8950 Indian rupees
TTEX https://tmsnrt.rs/3K1HJ5q
(Reporting by Urvi Dugar in Bengaluru; Editing by Eileen Soreng)
((UrviManoj.Dugar@thomsonreuters.com; +91 9558725583;))